APA (7th ed.) Citation

KA, C., H, V., H, N., EM, H., DW, S., R, C., . . . A, M. (2021). A phase 1 trial of the histone deacetylase inhibitor AR-42 in patients with neurofibromatosis type 2-associated tumors and advanced solid malignancies. Cancer chemotherapy and pharmacology, 87(5), 599. https://doi.org/10.1007/s00280-020-04229-3

Chicago Style (17th ed.) Citation

KA, Collier, et al. "A Phase 1 Trial of the Histone Deacetylase Inhibitor AR-42 in Patients with Neurofibromatosis Type 2-associated Tumors and Advanced Solid Malignancies." Cancer Chemotherapy and Pharmacology 87, no. 5 (2021): 599. https://doi.org/10.1007/s00280-020-04229-3.

MLA (9th ed.) Citation

KA, Collier, et al. "A Phase 1 Trial of the Histone Deacetylase Inhibitor AR-42 in Patients with Neurofibromatosis Type 2-associated Tumors and Advanced Solid Malignancies." Cancer Chemotherapy and Pharmacology, vol. 87, no. 5, 2021, p. 599, https://doi.org/10.1007/s00280-020-04229-3.